C12N 2730/10041
Use of virus, viral particle or viral elements as a vector
C12N2730/10041 (Use of virus, viral particle or viral elements as a vector) appears on 3 US grants and 4 published applications in this corpus.
Search patents in C12N- Granted patents
- 3
- Published applications
- 4
- Assignees
- 6
- Inventors
- 7
- Latest grant
- 8 Jul 2025
Filings by year
| Year | Granted patents | Published applications |
|---|---|---|
| 2016 | 0 | 2 |
| 2017 | 0 | 0 |
| 2018 | 0 | 0 |
| 2019 | 2 | 0 |
| 2020 | 0 | 0 |
| 2021 | 0 | 1 |
| 2022 | 0 | 0 |
| 2023 | 0 | 0 |
| 2024 | 0 | 0 |
| 2025 | 1 | 1 |
By publication year.
Subgroups
Granted patents
- C12N 2730/10043Viral genome or elements thereof as genetic vectorIndexing code3
- C12N 2730/10042Virus or viral particle as vehicleIndexing code0
- C12N 2730/10044Chimeric viral vector comprising heterologous viral elements for production of another viralIndexing code0
- C12N 2730/10045Special targeting system for viral vectorsIndexing code0
Recent patents
- Animal model for hepatocellular carcinoma and uses thereof8 Jul 2025US 12,349,665 B2National Yang-Ming University
- Modified hepatitis post-transcriptional regulatory elements30 Jul 2019US 10,363,269 B2Juno Therapeutics, Inc.
- Rodent hepadnavirus cores with reduced carrier-specific antigenicity28 May 2019US 10,300,124 B2VLP Biotech, Inc.
- Immunogens targeting anthrax15 May 2025US 2025/0152692 A1The Regents of the University of Michigan
- Animal model for hepatocellular carcinoma and uses thereof24 Jun 2021US 2021/0185991 A1National Yang-Ming University
- Modified hepatitis post-transcriptional regulatory elements14 Jul 2016US 2016/0199412 A1Juno Therapeutics, Inc.
- Rodent hepadnavirus cores with reduced carrier-specific antigenicity28 Jan 2016US 2016/0022801 A1VLP Biotech, Inc.
Most cited
By later US patents